Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

PURPOSE: Vorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM). PATIENTS AND METHODS: Patients with recurrent GBM who had received one or fewer chemotherapy regimens for progressive disease were eligible. Vorinostat was administered at...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Galanis, Evanthia, Jaeckle, Kurt A., Maurer, Matthew J., Reid, Joel M., Ames, Matthew M., Hardwick, James S., Reilly, John F., Loboda, Andrey, Nebozhyn, Michael, Fantin, Valeria R., Richon, Victoria M., Scheithauer, Bernd, Giannini, Caterina, Flynn, Patrick J., Moore, Dennis F., Zwiebel, James, Buckner, Jan C.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2009
Θέματα:
Original Reports
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2669764/
https://ncbi.nlm.nih.gov/pubmed/19307505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.0694
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια